These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 18780577)

  • 1. [What is the current treatment of patients with essential thrombocytopenia and other myeloproliferations accompanied with thrombocythemia [corrected] and what can be the predictive sign of the risk of thrombosis in such patients--a report from the registry of patients treated by Thromboreductine].
    Penka M; Schwarz J; Pavlík T; Pytiĺk R; Doubek M; Dulícek P; Kissová J; Hlusi A; Schutzová M; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Vozobulová V; Hadacová I; Hochová I; Voglová J; Dusek L
    Vnitr Lek; 2008; 54(7-8):775-82. PubMed ID: 18780577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Essential thrombocytemia and other myeloproliferations with thrombocytemia in the data of the register of patients treated with Thromboreductin till the end of 2006].
    Penka M; Schwarz J; Pavlík T; Pytlík R; Doubek M; Dulícek P; Pospísilová D; Kissová J; Hlusí A; Schützová M; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Vozobulová V; Hadacová I; Hochová I; Voglová J; Lhotanová T; Bubeník B; Zapletal O; Vránová M; Micaníková M; Dusek L
    Vnitr Lek; 2007 Jun; 53(6):653-61. PubMed ID: 17702125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The results of patients with essentials thrombocythemia and other myeloproliferation-related thrombocythemia--a report of patients treated with Thromboreductin].
    Penka M; Schwarz J; Pavlík T; Indrák K; Doubek M; Dulícek P; Pospísilová D; Kissová J; Jonásová A; Jelínková P; Hlusí A; Schutzová M; Cerná O; Brychtová Y; Nováková L; Korístek Z; Segethová J; Vozobulová V; Hadacová I; Hochová I; Voglová J; Walterová L; Bodzásová C; Dusek L
    Vnitr Lek; 2009 Nov; 55(11):I-XII. PubMed ID: 20017445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012].
    Penka M; Schwarz J; Ovesná P; Cervinek L; Dulíček P; Pospíšilová D; Kissová J; Pavlík T;
    Vnitr Lek; 2013 Jun; 59(6):516-31. PubMed ID: 23808749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Essential thrombocythaemia and other myeloproliferative disorders with thrombocythaemia treated with Thromboreductin. A report from the database of register for the 1st quarter of 2010].
    Penka M; Schwarz J; Ovesná P; Hlusí A; Korístek Z; Doubek M; Dulícek P; Pospísilová D; Kissová J; Buliková A; Pavlík T;
    Vnitr Lek; 2010 Jun; 56(6):503-12. PubMed ID: 20681462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin in essential thrombocythemia: status quo and quo vadis.
    Griesshammer M; Bangerter M; van Vliet HH; Michiels JJ
    Semin Thromb Hemost; 1997; 23(4):371-7. PubMed ID: 9263354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
    Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
    Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
    Iványi JL; Marton É; Plander M; Szendrei T
    Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
    Burkhard R; Adam H; Widmer L; Honegger HP
    Schweiz Med Wochenschr; 1998 Nov; 128(46):1808-12. PubMed ID: 9857387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Two clinical cases of essential thrombocythemia complicated by thrombosis in parturients].
    Vygovs'ka IaI; Karol' IuS; Ievstakhevich IuL; Diakiv HL; Buzherak NF; Vygovs'ka OIa; Masliak ZV
    Lik Sprava; 2011; (7-8):77-81. PubMed ID: 22768743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.
    Tefferi A; Silverstein MN; Petitt RM; Mesa RA; Solberg LA
    Semin Thromb Hemost; 1997; 23(4):379-83. PubMed ID: 9263355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
    Cacciola RR; Di Francesco E; Pezzella F; Tibullo D; Giustolisi R; Cacciola E
    Acta Haematol; 2007; 118(4):215-8. PubMed ID: 18057866
    [No Abstract]   [Full Text] [Related]  

  • 13. Indications for lowering platelet numbers in essential thrombocythemia.
    Barbui T
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):22-5. PubMed ID: 12682878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Primary thrombocythemia: diagnosis and therapy].
    Petrides PE
    Med Klin (Munich); 2006 Aug; 101(8):624-34. PubMed ID: 16896569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of essential thrombocythemia in childhood.
    Scherer S; Ferrari R; Rister M
    Pediatr Hematol Oncol; 2003; 20(5):361-5. PubMed ID: 12775533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
    Rey J; Viallard JF; Keddad K; Smith J; Wilde P; Kiladjian JJ;
    Eur J Haematol; 2014 Feb; 92(2):127-36. PubMed ID: 24118452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of platelet and white blood cell counts on major thrombosis - analysis from a patient registry in essential thrombocythemia.
    Buxhofer-Ausch V; Steurer M; Sormann S; Schloegl E; Schimetta W; Gisslinger B; Ruckser R; Gastl G; Gisslinger H
    Eur J Haematol; 2016 Dec; 97(6):511-516. PubMed ID: 27037858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anagrelide for treatment of patients with essential thrombocythaemia].
    Boban A; Sertić D; Radman I; Zupancić-Salek S; Zadro R; Labar B
    Lijec Vjesn; 2008; 130(5-6):141-5. PubMed ID: 18792562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When and how to treat essential thrombocythemia.
    Barbui T; Finazzi G
    N Engl J Med; 2005 Jul; 353(1):85-6. PubMed ID: 16000360
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.